No quarterly revenue total was found in PROPANC BIOPHARMA, INC.'s SEC filings.
Propanc Biopharma, Inc. (PPCB) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$1.6 million. As of Jun 30, 2026 it held $832,006 in cash and investments and $48,307 in total debt.
Revenue
—
Net income
$-4.57M
-12.3% vs year-ago quarter
Operating cash flow
$-1.60M
-1637.8% vs year-ago quarter
Free cash flow
$-1.60M
-40.2% vs prior quarter
EPS
$0.11
-90.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
6.33M
-50.6% vs year-ago quarter
Net cash
$783,699
Q4 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PPCB (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Camberwell, Victoria, Australia
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1517681
- Former names
- Propanc Health Group Corp (until Apr 5, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
Q4 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$3.5M | -$6.4M | -$3.7M | -$4.7M | -$3.6M |
| Net income | -$4.6M | -$6.4M | -$3.1M | -$4.8M | -$4.1M |
| Diluted EPS | $0.11 | -$0.28 | -$0.30 | -$0.39 | $1.12 |
| Operating cash flow | -$1.6M | -$1.1M | -$999,140 | -$1.9M | -$92,186 |
| Free cash flow | -$1.6M | -$1.1M | -$1.0M | -$1.9M | — |
| Total assets | $12.8M | $14.3M | $15.1M | $18.0M | $19.6M |
| Total liabilities | $3.4M | $3.5M | $3.7M | $3.6M | $5.7M |
| Stockholders' equity | $9.4M | $9.8M | $10.5M | $14.4M | $13.9M |
| Cash and investments | $832,006 | $443,702 | $561,237 | $602,737 | $12,088 |
| Total debt | $48,307 | $108,591 | $111,853 | $169,548 | $537,921 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Oct 29, 2026 | Oct 23, 2026 |
| 10-K | Annual report | Sep 25, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 14, 2026 | Jul 8, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 26, 2026 | Feb 20, 2026 |
| 10-Q | Quarterly report | Feb 17, 2026 | Dec 31, 2025 |
All 438 Propanc Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.